CO7071126A2 - Derivados de piridona - Google Patents

Derivados de piridona

Info

Publication number
CO7071126A2
CO7071126A2 CO14189810A CO14189810A CO7071126A2 CO 7071126 A2 CO7071126 A2 CO 7071126A2 CO 14189810 A CO14189810 A CO 14189810A CO 14189810 A CO14189810 A CO 14189810A CO 7071126 A2 CO7071126 A2 CO 7071126A2
Authority
CO
Colombia
Prior art keywords
pyridone derivatives
pyridone
derivatives
Prior art date
Application number
CO14189810A
Other languages
English (en)
Spanish (es)
Inventor
Hitoshi Ohki
Masahiro Ota
Hideaki Watanabe
Akitake Yamaguchi
Yoshihiro Shibata
Yuichi Tominaga
Takeshi Jimbo
Kosuke Takeuchi
Keijiro Kobayashi
Katsuhiro Kobayashi
Daisuke Fukatsu
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CO7071126A2 publication Critical patent/CO7071126A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO14189810A 2012-01-31 2014-08-28 Derivados de piridona CO7071126A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012017971 2012-01-31
US201261746039P 2012-12-26 2012-12-26

Publications (1)

Publication Number Publication Date
CO7071126A2 true CO7071126A2 (es) 2014-09-30

Family

ID=48905312

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14189810A CO7071126A2 (es) 2012-01-31 2014-08-28 Derivados de piridona

Country Status (30)

Country Link
US (1) US8933103B2 (https=)
EP (1) EP2810937B1 (https=)
JP (1) JP6006241B2 (https=)
KR (1) KR102078530B1 (https=)
CN (1) CN104185627B (https=)
AU (1) AU2013216006B2 (https=)
BR (1) BR112014018702B1 (https=)
CA (1) CA2863515C (https=)
CO (1) CO7071126A2 (https=)
CY (1) CY1118656T1 (https=)
DK (1) DK2810937T3 (https=)
ES (1) ES2617484T3 (https=)
HR (1) HRP20170303T1 (https=)
HU (1) HUE031624T2 (https=)
IL (1) IL233863A (https=)
LT (1) LT2810937T (https=)
MX (1) MX351812B (https=)
MY (1) MY165215A (https=)
NZ (1) NZ627586A (https=)
PH (1) PH12014501719B1 (https=)
PL (1) PL2810937T3 (https=)
PT (1) PT2810937T (https=)
RS (1) RS55728B1 (https=)
RU (1) RU2632885C2 (https=)
SG (1) SG11201404505PA (https=)
SI (1) SI2810937T1 (https=)
SM (2) SMT201700065T1 (https=)
TW (1) TWI537259B (https=)
WO (1) WO2013115280A1 (https=)
ZA (1) ZA201405486B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013162061A1 (ja) * 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
JP6493218B2 (ja) * 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
AU2014353006B2 (en) 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
US10233176B2 (en) 2013-11-27 2019-03-19 Signalchem Lifesciences Corporation Aminopyridine derivatives as TAM family kinase inhibitors
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
TWI723572B (zh) * 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
WO2017146236A1 (ja) 2016-02-26 2017-08-31 小野薬品工業株式会社 Axl阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
KR102483020B1 (ko) 2016-03-28 2023-01-04 인사이트 코포레이션 Tam 저해제로서의 피롤로트리아진 화합물
CN108250200A (zh) * 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
US20200197385A1 (en) 2017-08-23 2020-06-25 Ono Pharmaceutical Co., Ltd. Therapeutic agent for cancer containing axl inhibitor as active ingredient
MA50655B1 (fr) 2017-09-27 2021-11-30 Incyte Corp Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
EP3746070A4 (en) * 2018-01-29 2021-09-01 Capulus Therapeutics, LLC SREBP INHIBITORS WITH A 6-LINKED CENTER RING
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
TWI840378B (zh) 2018-07-04 2024-05-01 日商第一三共股份有限公司 二芳基吡啶衍生物之製造方法
ES2985569T3 (es) * 2018-08-24 2024-11-06 Transthera Sciences Nanjing Inc Nuevo inhibidor de derivado de quinolina
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
BR112022010082A2 (pt) * 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2022220227A1 (ja) * 2021-04-14 2022-10-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロピリドピリミジン化合物
WO2026014445A1 (ja) * 2024-07-09 2026-01-15 住友化学株式会社 ピリダジン誘導体及びそれを含有する組成物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE383153T1 (de) * 1999-05-07 2008-01-15 Encysive Pharmaceuticals Inc Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
EP1136485A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo Aminophenyl pyrimidone derivatives
IL163547A0 (en) 2002-02-12 2005-12-18 Quark Biotech Inc Use of the axl receptor for diagnosis and treatment of renal disease
US7884119B2 (en) 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
WO2007057399A2 (en) 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
PL1959955T3 (pl) 2005-12-05 2011-04-29 Pfizer Prod Inc Sposób traktowania nieprawidłowego wzrostu komórek
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2008083353A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
JP2010514810A (ja) 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ, インコーポレイテッド Axlインヒビターとして有用な置換トリアゾール
US8012965B2 (en) 2006-12-29 2011-09-06 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710046C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
EP2078010B1 (en) 2006-12-29 2014-01-29 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
US20100261723A1 (en) 2007-07-09 2010-10-14 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
RU2010120536A (ru) * 2007-10-25 2011-11-27 Астразенека Аб (Se) Производные пиридина и пиразина, полезные для лечения клеточных проферативных расстройств
JP2011500778A (ja) * 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−083
EP2205592B1 (en) 2007-10-26 2013-05-08 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
AU2008318854A1 (en) * 2007-11-02 2009-05-07 Janssen Pharmaceutica, N.V. Use of CFMS inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer
JP5693239B2 (ja) 2008-01-23 2015-04-01 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 4−ピリジノン化合物および癌についてのその使用
BRPI0906444B8 (pt) 2008-01-23 2021-05-25 Bristol Myers Squibb Co compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
RU2010146474A (ru) 2008-04-16 2012-05-27 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. (De) Производные хинолина в качестве ингибиторов axl киназ
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009138799A1 (en) 2008-05-14 2009-11-19 Astex Therapeutics Limited Therapeutic uses of 1-cycl0pr0pyl-3 - [3- ( 5 -morpholin- 4 -ylmethyl- 1h-benz0imidaz0l- 2 -yl) -lh-pyrazol-4-yl] -urea
JP5613156B2 (ja) 2008-07-09 2014-10-22 ライジェル ファーマシューティカルズ, インコーポレイテッド Axl阻害剤として有用な架橋二環ヘテロアリール置換トリアゾール
ES2537480T3 (es) 2008-07-09 2015-06-08 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl
TW201041892A (en) 2009-02-09 2010-12-01 Supergen Inc Pyrrolopyrimidinyl Axl kinase inhibitors
WO2010126914A1 (en) * 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
US8962623B2 (en) 2011-03-04 2015-02-24 Locus Pharmaceuticals, Inc. Aminopyrazine compounds

Also Published As

Publication number Publication date
SI2810937T1 (sl) 2017-01-31
PL2810937T3 (pl) 2017-07-31
KR20140117439A (ko) 2014-10-07
PH12014501719B1 (en) 2019-07-17
LT2810937T (lt) 2017-02-10
TWI537259B (zh) 2016-06-11
CY1118656T1 (el) 2017-07-12
JP6006241B2 (ja) 2016-10-12
US20130281428A1 (en) 2013-10-24
EP2810937B1 (en) 2016-11-30
EP2810937A4 (en) 2015-07-22
RU2014135401A (ru) 2016-03-20
SMT201700065B (it) 2017-03-08
CA2863515C (en) 2018-02-27
SG11201404505PA (en) 2014-10-30
IL233863A (en) 2017-08-31
HK1203504A1 (en) 2015-10-30
US8933103B2 (en) 2015-01-13
RS55728B1 (sr) 2017-07-31
SMT201700065T1 (it) 2017-03-08
CN104185627B (zh) 2018-01-12
HRP20170303T1 (hr) 2017-04-21
CA2863515A1 (en) 2013-08-08
IL233863A0 (en) 2014-09-30
BR112014018702B1 (pt) 2021-12-14
PT2810937T (pt) 2017-03-03
BR112014018702A2 (https=) 2017-06-20
BR112014018702A8 (pt) 2017-07-11
RU2632885C2 (ru) 2017-10-11
PH12014501719A1 (en) 2014-11-10
AU2013216006B2 (en) 2017-06-08
HUE031624T2 (en) 2017-07-28
AU2013216006A1 (en) 2014-08-28
TW201335148A (zh) 2013-09-01
MX351812B (es) 2017-10-27
WO2013115280A1 (ja) 2013-08-08
MX2014009246A (es) 2014-10-14
JPWO2013115280A1 (ja) 2015-05-11
MY165215A (en) 2018-03-09
DK2810937T3 (en) 2017-03-13
NZ627586A (en) 2016-08-26
ES2617484T3 (es) 2017-06-19
ZA201405486B (en) 2015-11-25
KR102078530B1 (ko) 2020-02-18
EP2810937A1 (en) 2014-12-10
CN104185627A (zh) 2014-12-03

Similar Documents

Publication Publication Date Title
CY2022027I1 (el) Παραγωγα βενζιμιδαζολο-προλινης
CO7071126A2 (es) Derivados de piridona
EP2813491A4 (en) CYCLO ALKAN DERIVATIVE
PT2944633T (pt) Derivado de piridina
PT2684880T (pt) Derivado de dispiropirrolidina
LT2903991T (lt) Antifibroziniai piridinonai
EP2807309A4 (en) ABFLUSSSIEB
EP2872093A4 (en) DIAPER PANTS
EP2872089A4 (en) CONTAINMENT TROUSERS
ZA201503969B (en) Novel pyridine derivatives
BR112015002950A2 (pt) novos derivados de bicíclico-piridina
EP2862861A4 (en) PIPERIDINYLPYRAZOLOPYRIDINDERIVAT
CO7020919A2 (es) Derivados de tetrahidro-quinazolinona
CO6960557A2 (es) Derivados de 2-yodo-imidazol
CO7020920A2 (es) Derivado de fenilazol sustituido
PT2665720E (pt) Derivados de 2-metoxi-piridin-4-ilo
EP2873660A4 (en) INDOLCARBOXAMIDDERIVAT
IL237128A0 (en) New pyridine derivatives
EP2832733A4 (en) 4-alkanoylamino-3-pyrazolone
FR2994990B1 (fr) Volet de desenfumage
TH148774B (th) อนุพันธ์ไบไซคลิค ไดไฮโดรควิโนลีน-2-โอนใหม่
ES1077863Y (es) Cubitera perfeccionada
ES1078331Y (es) Pieza de reposteria decorable
BR302012005101S1 (pt) Configuracao aplicada em sandalia
BR302012005073S1 (pt) Configuracao aplicada em sandalia